Top news
Eisai will receive a sizable $300 million upfront, but the real value of the deal will come if studies testing its drug Lenvima together with Keytruda bear fruit.
|
The FDA chief lambasted PBMs, insurers and branded drugmakers for allegedly blocking market entry of the copycat biologics.
|
It's the latest in vertical integration across the industry, after regulators blocked horizontal tie-ups in recent years.
|
In an industry on the cutting edge of innovation, you need a tech environment to match. .
|
The French pharma will license out 10 infectious disease assets to Evotec, transferring about 100 R&D staff to the German drug discovery company.
|
The Israeli biotech saw its stock drop more than 60% on the late-stage failure.
|
Feature Story
The IL-17 arena is getting pretty crowded, pushing drugmakers to explore various routes to market dominance.
|
Treatment with evobrutinib significantly reduced lesions characteristic of the disease compared to placebo.
|
The Israeli company is looking to change its image amid multiple challenges.
|
BROUGHT TO YOU BY – DTC Perspectives
Join the 18th Annual DTC National Conference
The 2018 DTC National agenda will feature the latest insights, research, and case studies on all aspects of DTC pharmaceutical marketing. See several innovative presentations around behaviorism and neuroscience, and gain insights from advanced research revealed for the first time at the DTC National. Learn more
What We're Reading
Bloomberg BNA
|
Reuters
|
CNN
|
Xconomy
|
Associated Press
|
Upcoming Event
Dive Into a Topic
|